Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe.

Division de Investigaciones en Neurociencias, Departamento de Cronobiología, Instituto Nacional de Psiquiatria Ramón de la Fuente, Tlalpan, Mexico, D.F.
Sleep (Impact Factor: 5.1). 06/2003; 26(3):259-64.
Source: PubMed

ABSTRACT The effect of a vasoactive intestinal peptide (VIP) microinjection into the amygdaloid central (CN) and basal nuclei (BN) on sleep organization and on the number and pattern of occurrence of pontogeniculooccipital (PGO) waves was analyzed.
One group of 8 cats was studied in baseline conditions and after the microinjection of two doses of VIP applied into the CN and BN.
Sleep research laboratory. PARTCIPANTS AND INTERVENTIONS: Eight cats were prepared with sleep-recording electrodes and with guide tubes in both amygdalae for saline and VIP microinjections. Neuropeptide doses of 0.10 microg/1 microl (30 microM) and 0.33 microg/1 microl (99.24 microM) were employed.
Once the microinjection was applied, 23-hour polygraphic sleep recordings were performed for 5 consecutive days. Concomitantly the PGO waves were tape-recorded on each day and computationally analyzed. Results show that the 0.10 microg/1 microl microinjection produced no change. Unilateral VIP 0.33 microg/1 microl injection into the CN provoked a significant and lasting increase in the percentage of slow-wave sleep with PGO waves. Bilateral application of VIP increased the percentage of slow-wave sleep with PGO waves and rapid eye movement sleep for 5 days. Bilateral microinjection of the neuropeptide into the BN only enhanced the percentage of slow wave sleep with PGO waves. For both amygdaloid nuclei, we observed that VIP increased the number and modified the PGO wave pattern of occurrence during slow-wave sleep with PGO waves and during rapid eye movement sleep.
The VIP microinjection into both the CN and BN induces increased amounts of rapid eye movement sleep, PGO waves, and slow-wave sleep with PGO waves, having a more robust effect on all of these three variables when applied into the CN.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A variety of medications representing several major drug classes improve cataplexy in patients with narcolepsy. These include aminergic reuptake inhibitors such as venlafaxine and clomipramine as well as sodium oxybate. This review is intended to familiarize readers with the safety and efficacy of these medications, thus enabling clinicians to optimize their management of cataplexy.
    Sleep Medicine Reviews 11/2004; 8(5):355-66. · 8.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Narcolepsy is a neurological disorder characterized, in its classical form, by excessive daytime sleepiness (EDS) with irresistible episodes of sleep, cataplexy, disrupted nocturnal sleep, hypnagogic/hypnopompic hallucinations and sleep paralysis. It is often under-diagnosed, however, if it is suitably diagnosed, symptoms can be well treated by means of targeted drugs, such as modafinil to treat EDS, sodium oxybate for cataplexy, as well as EDS and disrupted nocturnal sleep, and tricyclic and newer antidepressants for cataplexy. Hallucinations and sleep paralysis can be treated with the same drugs used for cataplexy. Amphetamines and amphetamine-like stimulants are used less nowadays. Behavioral measures are also important and useful. The discovery of hypocretin deficiency in narcoleptic patients opens new perspectives for the development of newer therapeutic approaches for both EDS and cataplexy. Therapy for narcolepsy is chronic, hence symptomatic. However, the correct use of available drugs enables patients to gain a better quality of life, keeping the symptoms under control, which, mainly from a social point of view, are heavily disabling.
    Expert Review of Neurotherapeutics 07/2009; 9(6):897-910. · 2.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Por las observaciones clínicas y experimentales se sabe que hay una relación entre la epilepsia y el sueño. Se describe durante el sueño de ondas lentas (SOL) una facilitación de la actividad epiléptica y una inhibición durante el sueño de movimientos oculares rápidos (MOR). A su vez, durante las crisis epilépticas se observa una inhibición del sueño y cuando no hay crisis, y sólo se registra actividad epiléptica, se observa un aumento en la sincronización cortical. La estimulación eléctrica del nervio vago (ENV) induce sincronización y desincronización de la actividad cortical según los parámetros de estimulación. Hemos descrito una inhibición de la actividad convulsiva generalizada inducida por la estimulación eléctrica (kindling) y química (penicilina) en la amígdala del lóbulo temporal. También se ha demostrado que la ENV induce la actividad ponto–genículo–occipital (PGO), por lo que se deduce que la ENV tiene influencia tanto en la epilepsia como en el sueño. El objetivo de este trabajo fue analizar el efecto de la estimulación eléctrica crónica del nervio vago sobre los cambios que induce la epilepsia en la organización temporal del sueño y la vigilia.
    Salud Mental 04/2012; 35(2):155-163. · 0.42 Impact Factor


Available from
Jun 6, 2014